Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior

被引:44
作者
Gueron, G. [1 ]
De Siervi, A. [1 ]
Vazquez, E. [1 ]
机构
[1] Univ Buenos Aires, Sch Sci, Dept Biol Chem, CONICET, RA-1428 Buenos Aires, DF, Argentina
关键词
castration-resistant prostate cancer (CRPC); metastasis; inflammation; chemokines; reactive oxygen species (ROS); NF-KAPPA-B; CHEMOKINE RECEPTOR; ANDROGEN RECEPTOR; HEME OXYGENASE-1; CELL-ADHESION; MATRIX METALLOPROTEINASES; MOLECULAR-MECHANISMS; SIGNALING PATHWAYS; CXCR4; EXPRESSION; GENE-EXPRESSION;
D O I
10.1038/pcan.2011.64
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is currently estimated that inflammatory responses are linked to 15-20% of all deaths from cancer worldwide. Although many studies point to an important role of inflammation in prostate growth, the contribution of inflammation to castration-resistant prostate cancer is not completely understood. The presence of inflammatory mediators in tumor microenvironment raises the question whether genetic events that participate in cancer development and progression are responsible for the inflammatory milieu inside and surrounding tumors. Activated oncogenes, cytokines, chemokines and their receptors, sustained oxidative stress and antioxidant imbalance share the capacity to orchestrate these pro-inflammatory programs; however, the diversity of the inflammatory cell components will determine the final response in the prostate tissue. These observations give rise to the concept that early genetic events generate an inflammatory microenvironment promoting prostate cancer progression and creating a continuous loop that stimulates a more aggressive stage. It is imperative to dissect the molecular pathologic mechanism of inflammation involved in the generation of the castration-resistant phenotype in prostate cancer. Here, we present a hypothesis where molecular signaling triggered by inflammatory mediators may evolve in prostate cancer progression. Thus, treatment of chronic inflammation may represent an important therapeutic target in advanced prostate cancer. Prostate Cancer and Prostatic Diseases (2012) 15, 213-221; doi:10.1038/pcan.2011.64; published online 20 December 2011
引用
收藏
页码:213 / 221
页数:9
相关论文
共 118 条
[1]   Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer [J].
Akashi, Takuya ;
Koizumi, Keiichi ;
Tsuneyama, Koichi ;
Saiki, Ikuo ;
Takano, Yasuo ;
Fuse, Hideki .
CANCER SCIENCE, 2008, 99 (03) :539-542
[2]   Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions [J].
Akech, J. ;
Wixted, J. J. ;
Bedard, K. ;
van der Deen, M. ;
Hussain, S. ;
Guise, T. A. ;
van Wijnen, A. J. ;
Stein, J. L. ;
Languino, L. R. ;
Altieri, D. C. ;
Pratap, J. ;
Keller, E. ;
Stein, G. S. ;
Lian, J. B. .
ONCOGENE, 2010, 29 (06) :811-821
[3]   B-cell-derived lymphotoxin promotes castration-resistant prostate cancer [J].
Ammirante, Massimo ;
Luo, Jun-Li ;
Grivennikov, Sergei ;
Nedospasov, Sergei ;
Karin, Michael .
NATURE, 2010, 464 (7286) :302-U187
[4]   Role of the metastasis-promoting protein osteopontin in the tumour microenvironment [J].
Anborgh, Pieter H. ;
Mutrie, Jennifer C. ;
Tuck, Alan B. ;
Chambers, Ann F. .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (08) :2037-2044
[5]   Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer [J].
Araki, Shinako ;
Omori, Yohei ;
Lyn, Dominic ;
Singh, Rajendra K. ;
Meinbach, David M. ;
Sandman, Yekutiel ;
Lokeshwar, Vinata B. ;
Lokeshwar, Bal L. .
CANCER RESEARCH, 2007, 67 (14) :6854-6862
[6]   RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor, metastasis genes [J].
Armstrong, Allison P. ;
Miller, Robert E. ;
Jones, Jon C. ;
Zhang, Jian ;
Keller, Evan T. ;
Dougall, William C. .
PROSTATE, 2008, 68 (01) :92-104
[7]   Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven [J].
Attard, Gerhardt ;
Reid, Alison H. M. ;
Olmos, David ;
de Bono, Johann S. .
CANCER RESEARCH, 2009, 69 (12) :4937-4940
[8]   CXCL12 activates a robust transcriptional response in human prostate epithelial cells [J].
Begley, Lesa A. ;
MacDonald, James W. ;
Day, Mark L. ;
Macoska, Jill A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (37) :26767-26774
[9]   Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway [J].
Bendre, MS ;
Margulies, AG ;
Walser, B ;
Akel, NS ;
Bhattacharrya, S ;
Skinner, RA ;
Swain, F ;
Ramani, V ;
Mohammad, KS ;
Wessner, LL ;
Martinez, A ;
Guise, TA ;
Chirgwin, JM ;
Gaddy, D ;
Suva, LJ .
CANCER RESEARCH, 2005, 65 (23) :11001-11009
[10]   Molecular alterations in primary prostate cancer after androgen ablation therapy [J].
Best, CJM ;
Gillespie, JW ;
Yi, YJ ;
Chandramouli, GVR ;
Perlmutter, MA ;
Gathright, Y ;
Erickson, HS ;
Georgevich, L ;
Tangrea, MA ;
Duray, PH ;
González, S ;
Velasco, A ;
Linehan, WM ;
Matusik, RJ ;
Price, DK ;
Figg, WD ;
Emmert-Buck, MR ;
Chuaqui, RF .
CLINICAL CANCER RESEARCH, 2005, 11 (19) :6823-6834